THANK YOU FOR SUBSCRIBING
Juvenescence, a UK start-up developing anti-ageing old cures, has raised $50m in Series A financing, with another $100m funding spherical deliberate for later this year and an initial public supplying in 2019.
The company is chaired via Jim Mellon, a billionaire investor who has turn out to be a passionate suggest of the use of latest clinical advances to promote longevity.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Since its inception in October 2016 Juvenescence has raised $13m in seed finance, followed by $50m series A funding involving a variety of international investors.
Juvenescence is developing a team of 20 scientists and drug developers in London who will co-ordinate its investments.
Juvenescence’s portfolio currently includes: Insilico Medicine, a next-generation artificial intelligence company specialising in the application of deep learning to drug discovery and aging research; Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds; NetraPharma, a joint venture using artificial intelligence to improve clinical trial design; LyGenesis, a company with technology to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organs; and AgeX Therapeutics, a company applying intellectual property related to cell immortality and pluripotency to biogerontology.
Check out: Financial Tech Review
More in News